A complex composition for preventing or treating respiratory diseases comprising a extract of Eriobotrya japonica and Platycodon grandiflorus

Abstract

The present invention relates to a composition for improving, preventing, or treating respiratory diseases, comprising a complex of loquat extract and balloon flower extract as an active ingredient. By including a complex of loquat extract and balloon flower extract in a specific ratio as an active ingredient, the composition exhibits excellent anti-inflammatory, mucus gene (MUC5AC) oversecretion inhibition, and antitussive effects, thereby being effective in improving, preventing, or treating respiratory diseases and the symptoms caused thereby.

Description

Technology Field

[0001] The present invention relates to a composition for improving, preventing, or treating respiratory diseases using a complex of loquat extract and balloon flower extract as an active ingredient, and more specifically, to a composition effective for improving, preventing, or treating respiratory diseases and symptoms caused thereby by containing a complex of loquat extract and balloon flower extract mixed in a specific ratio as an active ingredient, which has excellent anti-inflammatory, mucus gene (MUC5AC) oversecretion inhibition, and antitussive effects, and to the development of a food or health functional food containing said composition. Background Technology

[0002] Respiratory diseases cause various symptoms such as cough, phlegm, shortness of breath, and chest pain, and in some cases, may be accompanied by systemic fatigue, headache, and malaise. Representative diseases include asthma, chronic obstructive pulmonary disease (COPD), and bronchitis, and treatments for these conditions primarily involve anti-inflammatory drugs, bronchodilators, and antihistamines. However, existing treatments focus mainly on alleviating specific symptoms, limiting their ability to comprehensively address the diverse symptoms of respiratory diseases. In particular, issues such as drug resistance and side effects have frequently occurred with long-term use. Accordingly, there is a demand for the development of new effective treatments utilizing naturally derived ingredients that minimize side effects.

[0003] Meanwhile, the market size for respiratory disease treatments is projected to reach $269.5 billion during the forecast period from 2022 to 2026 (Global Respiratory Drugs Market 2022-2026, TechNavio). This reflects the continuing increase in demand for treatments and pharmaceuticals related to respiratory diseases, and such market growth can be seen as an indication of the importance of respiratory diseases and the need for treatment. The development of compositions for improving and treating respiratory health using seafood, which has a long history of being consumed as food, is superior in terms of safety as it may exhibit fewer side effects and allergic reactions compared to synthetic drugs; furthermore, it is believed that consumers will feel less aversion when developed as functional foods.

[0004] Accordingly, the present invention aims to provide a food composition and a pharmaceutical composition that utilize a complex of natural extracts of loquat and balloon flower, which are excellent in terms of safety, and exhibit anti-inflammatory effects, an inhibitory effect on the oversecretion of mucus gene (MUC5AC) protein, and antitussive effects, thereby showing excellent effects in improving respiratory diseases.

[0005] In particular, the present invention aims to overcome the problems of efficacy saturation or toxicity that are difficult to resolve with single materials by utilizing a complex of loquat extract and balloon flower extract. That is, the present invention aims to solve the problem of limiting usage due to toxicity or the difficulty in achieving sufficient efficacy when using single materials, or the difficulty in achieving sufficient efficacy due to high concentrations exceeding a certain level, by providing a complex, and aims to provide a composition effective for the improvement, prevention, or treatment of respiratory diseases by including the said complex. Prior art literature

[0006] Korean Registered Patent No. 10-2442455 (registered September 6, 2022) describes a composition for improving respiratory diseases using natural products and a method for manufacturing the same. Korean Registered Patent No. 10-2221389 (registered February 23, 2021) describes a composition for treating respiratory diseases induced by yellow dust and fine dust, containing a herbal extract as an active ingredient. The problem to be solved

[0007] The present invention aims to provide a composition that exhibits excellent effects in improving, preventing, or treating respiratory diseases through anti-inflammatory effects, inhibition of mucus gene protein oversecretion, and antitussive effects by using a 'balloon flower-loquat complex' comprising a combination of loquat extract and balloon flower extract. means of solving the problem

[0008] The present invention provides a food composition for improving respiratory diseases containing, as an active ingredient, a balloon flower-loquat complex comprising a mixture of balloon flower extract and loquat extract.

[0009] The present invention provides a pharmaceutical composition for the prevention or treatment of respiratory diseases containing, as an active ingredient, a balloon flower-loquat complex comprising a mixture of balloon flower extract and loquat extract.

[0010] In the present invention, the balloon flower extract is preferably obtained by hot water extraction at 45 to 65°C for 6 to 12 hours, and the loquat extract is preferably obtained by ethanol extraction at 35 to 55°C for 4 to 10 hours.

[0011] In the present invention, the symptoms of the respiratory disease may be characterized by being one or more selected from inflammation, phlegm, runny nose, and cough. Effects of the invention

[0012] The present invention provides a composition that exhibits excellent effects in improving, preventing, and treating respiratory diseases through anti-inflammatory effects, inhibition of mucus gene protein oversecretion, and antitussive effects by containing a 'balloon flower-loquat complex' comprising a combination of loquat extract and balloon flower extract as an active ingredient. Brief explanation of the drawing

[0013] Figure 1 is the result of comparing and confirming the IL-6 cytokine concentration of balloon flower-loquat complexes (Examples 1-1 to 1-5) according to the mixing ratio. Figure 2 shows the NO assay results of balloon flower-loquat complexes (Examples 1-1 to 1-5) according to the mixing ratio. Figure 3 is the result of a dot blot assay performed to evaluate the inhibitory effect of the balloon flower-loquat complex (6:4) on the oversecretion of mucus gene protein (MUC5AC). Specific details for implementing the invention

[0014] The present invention provides a food composition for improving symptoms of respiratory diseases containing a balloon flower-loquat complex, prepared by mixing balloon flower extract and loquat extract, as an active ingredient. Additionally, the present invention provides a pharmaceutical composition for the prevention or treatment of symptoms of respiratory diseases containing a balloon flower-loquat complex, prepared by mixing balloon flower extract and loquat extract, as an active ingredient.

[0015] balloon flower( Platycodon grandiflorus ) is the Campanulaceae family ( Campanulaceae It is a perennial plant belonging to the family Platycodon grandiflorus, and has been widely used for food and medicinal purposes in East Asia (especially Korea, China, and Japan). In Korea, balloon flower root is consumed in various forms, such as seasoned greens, pickles, juice, tea, and herbal prescriptions, with the root being the most commonly utilized part. Meanwhile, balloon flower root contains various bioactive substances such as saponins, polyphenols, flavonoids, and inulin, and is widely used in food, cosmetics, and health functional foods.

[0016] Biwa ( Eriobotrya japonica ) is the Rosaceae family ( Rosaceae It is an evergreen broad-leaved fruit tree belonging to the family Loquat, and is mainly cultivated in southern Korea, Japan, China, Southeast Asia, and the Mediterranean region. Various parts of the loquat, including the fruit, leaves, seeds, and flowers, have been utilized as traditional medicinal and food ingredients, with the leaves being particularly widely used.

[0017] Meanwhile, although some studies have previously utilized balloon flower and loquat extracts individually, this invention aims to develop and provide a composition that exhibits excellent efficacy in improving respiratory diseases and various associated symptoms by combining balloon flower and loquat, which are commonly used as herbal medicines, thereby demonstrating enhanced antitussive and anti-inflammatory effects compared to single components of balloon flower or loquat.

[0018] Accordingly, the inventors of the present invention, through diligent efforts, have developed a balloon flower-loquat complex that exhibits superior anti-inflammatory, mucus gene protein oversecretion inhibitory, and antitussive effects compared to the individual extracts of balloon flower extract and loquat extract, thereby exhibiting excellent improvement effects on symptoms of respiratory diseases, and intend to provide a composition for improving, preventing, or treating respiratory diseases using this.

[0019] Furthermore, the present invention utilizes loquat extract and balloon flower extract as a complex, thereby overcoming issues of efficacy saturation or toxicity that are difficult to resolve with single materials. In other words, the present invention resolves problems such as the difficulty in achieving sufficient efficacy due to high concentrations exceeding a certain level when using single materials, or usage limits due to toxicity, by providing a complex. Consequently, the invention provides a composition effective for the improvement, prevention, or treatment of respiratory diseases by including the aforementioned balloon flower-loquat complex. Meanwhile, the above composition can be utilized as a food or a health functional food.

[0020] In the following experiment of the present invention, the anti-inflammatory effect, the effect of inhibiting the oversecretion of mucus gene protein (MUC5AC), and the antitussive effect (cough suppression effect) of a balloon flower-loquat complex mixed with balloon flower extract and loquat extract were confirmed.

[0021] Meanwhile, in the composition of the present invention, the balloon flower extract is preferably extracted at 40 to 70°C for 4 to 24 hours, and more preferably may be extracted with hot water at 45 to 65°C for 6 to 12 hours. The loquat extract is preferably extracted at 25 to 60°C for 3 to 16 hours, and more preferably prepared by extracting at 35 to 55°C for 4 to 10 hours.

[0022] At this time, water, ethanol, or a mixture thereof may be used as the extraction solvent during the above extraction. In the case of balloon flower extract, it is preferable to extract with water, and in the case of loquat extract, it is preferable to extract using a mixture of water and ethanol. At this time, it is preferable to use a solvent mixed with water and ethanol in a weight ratio of 1:0.1 to 10, more preferably with a weight ratio of 1:0.5 to 1.5, and most preferably with a weight ratio of 1:1.

[0023] The above extraction solvent can preferably be added in an amount of 10 to 50 times the weight of each balloon flower root and loquat, and more preferably in an amount of 20 to 30 times the weight of each balloon flower root and loquat.

[0024] Preferably, the balloon flower extract and loquat extract are mixed in a ratio of 2.33:1 to 1:1 to prepare a balloon flower-loquat complex. More preferably, the balloon flower extract and loquat extract are mixed in a weight ratio of 6:4 based on a total weight of 10 to prepare a balloon flower-loquat complex. Through the following experiments, it was confirmed that the balloon flower-loquat complex mixed with balloon flower extract and loquat extract in a 6:4 ratio exhibits superior anti-inflammatory effects compared to the individual extracts of balloon flower and loquat, as well as superior inhibitory effects on mucus gene protein (MUC5AC) oversecretion and antitussive efficacy (cough suppression effect).

[0025] Meanwhile, in the present invention, the respiratory disease symptoms may be characterized by being one or more selected from inflammation, phlegm, runny nose, and cough. Respiratory diseases include asthma, chronic obstructive pulmonary disease (COPD), bronchitis, etc., and may cause symptoms such as cough, phlegm, shortness of breath, and chest pain. The composition of the present invention can exhibit an improving or therapeutic effect on both respiratory diseases and the symptoms caused thereby.

[0027] The content of the present invention will be explained in more detail below in the following examples or experimental examples, but the scope of the present invention is not limited to the following examples or experimental examples and includes variations of equivalent technical concepts.

[0029] [Example 1: Preparation of Balloon Flower-Loquat Compound]

[0030] In this example, balloon flower extract and loquat extract were prepared separately, and each extract was mixed according to the ratio in Table 1 below to prepare the balloon flower-loquat complexes of Examples 1-1 to 1-5.

[0031] Balloon flower extract was prepared by hot water extraction at 50°C for 11 hours, and loquat extract was prepared by extracting with 50% ethanol at 40°C for 8 hours. Then, the prepared balloon flower extract and loquat extract were mixed in weight ratios of 9:1, 8:2, 7:3, 6:4, and 5:5, respectively, to prepare balloon flower-loquat complexes according to the mixing ratios. Meanwhile, the balloon flower extract was extracted from the root portion of the balloon flower, and the loquat extract was extracted from the leaves of the loquat.

[0032] Sample name Balloon flower extract : Loquat extract Example 1-1 9 : 1 Examples 1-2 8 : 2 Examples 1-3 7 : 3 Examples 1-4 6 : 4 Examples 1-5 5 : 5

[0034] [Experimental Example 1: Confirmation of Anti-inflammatory Efficacy of Balloon Flower-Loquat Complex According to Mixing Ratio]

[0035] In this experiment, we intended to compare and evaluate the anti-inflammatory effects of the balloon flower-loquat complex (Examples 1-1 to 1-5) according to the mixing ratios prepared in Example 1 by confirming the secretion of Human IL-6 cytokine. Meanwhile, we intended to determine if there was a mixing ratio in which the anti-inflammatory efficacy was higher compared to the loquat extract alone when treated with the balloon flower-loquat complex by treating with the loquat extract alone (control group for each mixing ratio).

[0036] As shown in Figure 1, the experimental results confirmed that the anti-inflammatory efficacy was similar in the balloon flower-loquat complexes with mixing ratios of 7:3, 6:4, and 5:5, as the IL-6 cytokine concentrations were similar. In addition, at ratios of 9:1 and 8:2, significantly higher anti-inflammatory effects were observed compared to treatment with loquat extract alone or the complex; however, at mixing ratios of 7:3, 6:4, and 5:5, it was confirmed that there was no significant difference between the balloon flower-loquat complex and loquat extract alone. Accordingly, the mixing ratio was determined so that the proportion of loquat extract was 30% by weight or more.

[0038] [Experimental Example 2: Confirmation of Anti-inflammatory Efficacy of Balloon Flower-Loquat Complex According to Mixing Ratio]

[0039] In this experiment, an NO assay was performed to compare and evaluate the anti-inflammatory effects of balloon flower-loquat complexes (Examples 1-1 to 1-5) according to the mixing ratio prepared in Example 1 above.

[0040] As shown in Figure 2, the experimental results showed that, similar to Experimental Example 1, the NO level tended to decrease as the ratio of EJE (loquat extract) increased, and the anti-inflammatory efficacy tended to decrease when the ratio was increased to 5:5. Accordingly, the 6:4 (Platycodon:Loquat) composition was selected as the ratio in which the proportion of loquat is high and the efficacy is judged to be the best.

[0042] [Experimental Example 3: Comparison of the Inhibitory Effect of Balloon Flower-Loquat Complex on Mucus Gene (MUC5AC) Hypersecretion]

[0043] In this experiment, we intended to compare and evaluate the inhibitory effect on mucus gene (MUC5AC) oversecretion of the balloon flower-loquat complex (6:4) selected as the optimal ratio in Experimental Examples 1 and 2 above. Accordingly, a Dot Blot Assay was performed to evaluate the effect of the 6:4 complex of balloon flower (PGE) and loquat (EGE) on the secretion of MUC5AC protein induced by PMA.

[0044] As shown in Figure 3, the experimental results showed that PGE inhibited MUC5AC secretion at concentrations of 100 μg / mL or higher, while EJE showed an excellent inhibitory effect at a low concentration of 40 μg / mL. In particular, relatively high MUC5AC secretion was observed at a concentration of 60 μg / mL when PGE was treated alone, but it was confirmed that MUC5AC secretion was effectively reduced when EJE was mixed with PGE at the same concentration in a 6:4 ratio.

[0045] In other words, it was found that the balloon flower-loquat complex of the present invention has excellent efficacy in inhibiting the oversecretion of the mucus gene (MUC5AC) compared to balloon flower or loquat extracts alone.

[0047] [Experimental Example 4: Evaluation of Antitussive Efficacy of Balloon Flower-Loquat Complex in Guinea Pigs]

[0048] In this experiment, we aimed to compare and evaluate the antitussive efficacy of the balloon flower-loquat complex of the present invention against single extracts of balloon flower or loquat.

[0049] To confirm the antitussive effects of single extracts of Platycodon grandiflorus (Test Substance A) and Loquat (Test Substance B), and a Platycodon grandiflorus-Loquat complex, a tendency for coughing frequency to decrease was observed in guinea pigs (Hartley breed) after administering the single extract or the Platycodon grandiflorus-Loquat (6:4) complex, followed by inducing coughing with 7.5% citric acid. The test substances were administered for 3 days, and coughing was induced with 7.5% citric acid 1 hour after the last administration.

[0050] Meanwhile, the composition of the experimental group was designed to comprehensively evaluate the synergistic effect of the balloon flower-loquat complex (G1, G2, G4, G6), the efficacy evaluation of the balloon flower-loquat complex by concentration (G1, G2, G3), the efficacy evaluation between single extracts of balloon flower and loquat (G1, G4, G6), and the efficacy evaluation by concentration of each extract (G1, G4, G5; G1, G6, G7), and the results are shown in Table 2.

[0051] Group Cough frequency (Mean) Inhibitory ability (%) G1 Vehicle 34.1 0 G2 AB mixture (6:4) 800 mg / kg 19.7 42.29828851 G3 AB mixture (6:4) 400 mg / kg 20.8 38.87530562 G4 A single 400 mg / kg 25.4 25.55012225 G5 A single 240 mg / kg 28.2 17.3594132 G6 B single 400 mg / kg 27.1 20.53789731 G7 B single 160 mg / kg 22.0 35.45232274

[0053] As shown in Table 2, the balloon flower-loquat complex of the present invention exhibited an antitussive effect by suppressing cough in a concentration-dependent manner in a guinea pig cough-inducing model. In addition, the balloon flower-loquat complex was found to have superior antitussive efficacy (cough suppression rate) compared to treatment with balloon flower or loquat single extracts at concentrations of 400 and 800 mg / kg.

[0054] In other words, it was found that the balloon flower-loquat complex of the present invention has a concentration-dependent antitussive effect and possesses superior antitussive efficacy compared to single extracts of balloon flower or loquat.

Claims

Claim 1 A food composition for improving respiratory diseases, comprising a balloon flower-loquat complex mixed with balloon flower extract and loquat extract as an active ingredient, wherein the balloon flower-loquat complex is prepared by mixing balloon flower extract and loquat extract in a weight ratio of 2.33:1 to 1:

1. Claim 2 A pharmaceutical composition for the prevention or treatment of respiratory diseases, comprising a balloon flower-loquat complex mixed with balloon flower extract and loquat extract as an active ingredient, wherein the balloon flower-loquat complex is prepared by mixing balloon flower extract and loquat extract in a weight ratio of 2.33:1 to 1:

1. Claim 3 A composition according to claim 1 or 2, characterized in that the balloon flower extract is obtained by hot water extraction at 45 to 65°C for 6 to 12 hours, and the loquat extract is obtained by ethanol extraction at 35 to 55°C for 4 to 10 hours. Claim 4 A composition according to claim 1 or 2, characterized in that the symptoms of the respiratory disease are one or more selected from inflammation, phlegm, runny nose, and cough.

Images